<DOC>
	<DOCNO>NCT00464399</DOCNO>
	<brief_summary>To evaluate safety tolerability early switch everolimus cyclosporine A de novo renal transplant recipient assess rejection rate everolimus trough level , safety laboratory variable adverse event .</brief_summary>
	<brief_title>Feasibility Safety Early Switch Everolimus From Cyclosporine de Novo Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Male female age 18 year . Patients receive first second single renal transplant decease live donor Patient willing capable give write informed consent study participation Patients treat induction therapy time transplantation Patients maintain triple immunosuppressive regime consist cyclosporine ( C0 h 100250 ng/ml C2 h 9001100 ng/ml ) , Enteric coat mycophenolate sodium ( ECMPS ) , minimum dose 1080 mg corticosteroid , minimum dose 10 mg Patients without biopsy proven acute rejection episode treatment acute rejection since transplant Females capable become pregnant must negative pregnancy test prior switch everolimus require practice medically approve method birth control duration study period 8 week follow discontinuation study medication , even history infertility . Recipient multiorgan transplant , previously transplant organ different kidney transplant Patients antibodies towards donor kidney 30 % Patients receive renal transplant HLAidentical sibling Presence hyper sensitivity drug similar everolimus ( e.g . macrolides ) Patient past ( within last two year ) present malignancy excise basal cell squamous cell carcinoma skin Patients recipient AB0 incompatible transplant Patients unsuitable laboratory value Patients ongoing wound heal problem severe surgical complication opinion investigator Patient current severe major local systemic infection Patients require dialysis and/or calculate glomerular filtration rate ( CockcroftGault ) &lt; 20 ml/min Presence intractable immunosuppressant complication side effect ( e.g. , severe gastrointestinal adverse event ) time switch Patients HIV positive Hepatitis B surface antigen positive Hepatitis C virus positive . Recipients organs donor test positive Hepatitis B surface antigen Hepatitis C exclude . Evidence severe liver disease Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>De novo renal transplantation</keyword>
	<keyword>CNI-free protocol</keyword>
	<keyword>adult</keyword>
	<keyword>everolimus</keyword>
	<keyword>rejection</keyword>
</DOC>